An Off-the-Shelf Cancer Vaccine Faces a Final Clinical Hurdle in NSCLC

Episode Summary

Executive Summary: OSE Immunotherapeutics CEO Nicholas Poria explains how the company applies immune-system biology across oncology and inflammation, highlighting its off-the-shelf cancer vaccine Tidepi in phase 3 non-small cell lung cancer, its checkpoint and myeloid platforms, and partnering strategy with AbbVie and Beringer/Ingelheim to de-risk development and expand reach.

Main Topics: OSE’s cross-disciplinary immunology strategy (Priority: 5/5): Poria describes how the company learns bidirectionally between oncology and immunoinflammation, using insights from one field to inform the other. OSE279 and bifunctional anti-PD-1 platform (Priority: 4/5): The company’s proprietary anti-PD-1 backbone can be fused with cytokines or other immune stimulators to target tumor-specific T cells more precisely. OSE-172 and myeloid checkpoint inhibition (Priority: 4/5): OSE-172 targets SIRPα to release the innate immune system’s myeloid cells, complementing T-cell checkpoint inhibition. OSE 230 and pro-resolutive inflammation therapy (Priority: 4/5): The pro-resolutive monoclonal antibody platform aims to resolve inflammation by targeting tissue neutrophils through KEMER23 while preserving peripheral neutrophil function. Tidepi cancer vaccine and unmet need in NSCLC (Priority: 5/5): OSE’s lead program is an off-the-shelf therapeutic vaccine for metastatic NSCLC, a large market with many patients who no longer respond to PD-1-based therapy. Clinical and biomarker strategy for vaccine development (Priority: 5/5): Tidepi uses shared tumor antigens, neo-epitope engineering, and HLA-A2 patient selection via companion diagnostics to improve the chance of response. Partnership-driven development model (Priority: 4/5): OSE relies on large pharma collaborations to fund, validate, and advance programs while keeping internal focus on innovation and selective commercialization.

Key Arguments: OSE’s immuno-oncology and inflammation work are mutually informative because both involve understanding how immune responses are activated, suppressed, or misdirected. OSE279 is designed to improve on current PD-1 therapies by targeting immune-modulating payloads to PD-1-expressing tumor-reactive T cells, aiming for higher efficacy without added toxicity. OSE-172 extends checkpoint blockade into innate immunity by releasing the SIRPα brake on myeloid cells, creating a potential dual-checkpoint combination with PD-1 inhibitors. OSE 230 takes a different approach to inflammation by promoting resolution rather than broad suppression, preserving protective neutrophil function in the bloodstream. Therapeutic cancer vaccines struggled historically because of incomplete understanding of tumor microenvironments and limited molecular engineering, but those gaps have now narrowed. Tidepi is positioned as an off-the-shelf vaccine because metastatic NSCLC patients need immediate treatment and cannot wait weeks for personalized manufacturing. OSE selected shared antigens across cancers and engineered epitopes into neo-epitopes to improve immunogenicity and reduce escape risk. HLA-A2 selection is used because the vaccine’s epitopes bind that allele effectively, allowing a companion diagnostic to enrich for biological responders. Prior phase 3 data suggest Tidepi can outperform chemotherapy in some later-line NSCLC patients who have acquired resistance to immunotherapy, with better survival and less toxicity. The company believes partnerships are best for large, capital-intensive development programs, while internal development remains best for innovation-heavy projects with clearer targeted-market paths.

Data Points: Phase 3 program status: Ongoing - Tidepi confirmatory phase 3 in second-line non-small cell lung cancer has been initiated in the US, Europe, UK, and Canada. HLA-A2 prevalence: ~45% - OSE says HLA-A2 is present in nearly 45% of populations in Europe and the US, slightly more in China. NSCLC response gap: 60-70% nonresponse - Poria says the majority of patients do not respond to PD-1 immunotherapy in lung cancer. One-year survival with vaccine: 44% - Previously reported phase 3 NSCLC data for vaccine monotherapy versus chemotherapy. One-year survival with chemotherapy: 27% - Comparator in the prior phase 3 study. Toxicity reduction: ~3x less toxicity - Patients on the vaccine had threefold less toxicity than chemotherapy in prior phase 3 data. AbbVie upfront payment: $48 million - Upfront payment tied to OSE 230 collaboration. AbbVie potential milestones: $665 million - Additional contingent payments possible under the OSE 230 deal. Beringer/Ingelheim partnership potential: More than $1 billion - Total potential milestones and cross-royalties cited for the collaboration. Total partnership potential: ~$2 billion - Poria says OSE has three partnerships totaling roughly two billion in potential value. Number of shared tumor antigens: 5 - OSE identified five shared tumor antigens for the vaccine platform. Number of ongoing combination phase 2 studies: 3 - Tidepi is being tested in three independent combination studies.

Pivotal Quotes: "we are really learning from one field to the other" — Nicholas Poria: Explaining the interplay between oncology and immunoinflammation research at OSE. "the patients survive longer and better when they have developed this acquired resistance to immunotherapy" — Nicholas Poria: Summarizing prior Tidepi phase 3 findings in non-small cell lung cancer. "we are strong to innovate ... but where the large companies are really strong is for commercialization distribution" — Nicholas Poria: Describing why OSE favors partnerships for later-stage development and commercialization.

Implications: OSE is betting that biomarker-guided, off-the-shelf immunotherapies can fill major gaps left by current checkpoint drugs, especially in NSCLC. If phase 3 data hold, the company could validate a scalable vaccine model and strengthen its partnering-led path to market.